Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP19A1 | P11511 | 2/20 | 0.63 |
| ▸ | G6PD | P11413 | 2/20 | 0.50 |
| ▸ | HSD17B3 | P37058 | 2/20 | 0.44 |
| ▸ | GPBAR1 | Q8TDU6 | 5/20 | 0.43 |
| ▸ | LMNA | P02545 | 4/20 | 0.43 |
| ▸ | MEN1 | O00255 | 4/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.43 |
| ▸ | AKR1B10 | O60218 | 3/20 | 0.43 |
| ▸ | AKR1B1 | P15121 | 3/20 | 0.43 |
| ▸ | SHBG | P04278 | 2/20 | 0.43 |
| ▸ | SERPINA6 | P08185 | 2/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.43 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.43 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.43 |
| ▸ | EFNA1 | P20827 | 1/20 | 0.43 |
| ▸ | EPHA2 | P29317 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15094423 | 1.00 | CYP19A1 (0.63) | CYP19A1G6PDHSD17B3GPBAR1LMNA | |
| SCHEMBL502482 | 1.00 | CYP19A1 (0.63) | CYP19A1G6PDHSD17B3GPBAR1LMNA | |
| SCHEMBL502481 | 1.00 | CYP19A1 (0.63) | CYP19A1G6PDHSD17B3GPBAR1LMNA | |
| SCHEMBL503217 | 0.85 | CYP19A1 (0.61) | CYP19A1G6PDHSD17B3GPBAR1LMNA | |
| SCHEMBL502992 | 0.85 | CYP19A1 (0.61) | CYP19A1G6PDHSD17B3GPBAR1LMNA | |
| SCHEMBL8528354 | 0.85 | G6PD (0.69) | CYP19A1G6PDHSD17B3GPBAR1LMNA | |
| SCHEMBL5312818 | 0.85 | CYP19A1 (0.61) | CYP19A1G6PDHSD17B3GPBAR1LMNA | |
| SCHEMBL502993 | 0.85 | CYP19A1 (0.61) | CYP19A1G6PDHSD17B3GPBAR1LMNA | |
| SCHEMBL9764804 | 0.85 | G6PD (0.69) | CYP19A1G6PDHSD17B3GPBAR1LMNA | |
| SCHEMBL8640096 | 0.85 | G6PD (0.69) | CYP19A1G6PDHSD17B3GPBAR1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150071904-A1 | COMPOSITIONS AND METHODS TO BOOST ENDOGENOUS ROS PRODUCTION FROM BACTERIA | TRUSTEES OF BOSTON UNIVERSITY | 2015-03-12 | — | — | US | disclosed |
| US-20140220152-A1 | Compositions and Methods for Detecting, Treating, or Preventing Reductive Stress | UNIVERSITY OF UTAH RESEARCH FOUNDATION (US) | 2014-08-07 | — | — | US | disclosed |
| US-20120030779-A1 | COMPOSITIONS AND METHODS FOR DETECTING, TREATING, OR PREVENTING REDUCTIVE STRESS | UNIVERSITY OF UTAH RESEARCH FOUNDTION (UT) | 2012-02-02 | — | — | US | disclosed |
| US-5744462-A | ADMINISTERING GLUCOSE-6-PHOSPHATE DEHYDROGENASE INHIBITOR | RESEARCH CORPORATION TECHNOLOGIES, INC. (US) | 1998-04-28 | — | — | US | disclosed |
| US-5700793-A | AN ANDROSTANE-17-ONE AND ENE STEROIDS; HYPOGLYCEMIC AGENT, ANTICHOLESTEROL AGENT; TREATING AUTOIMMUNE DISEASES | RESEARCH CORPORATION TECHNOLOGIES, INC. (US) | 1997-12-23 | — | — | US | disclosed |
| US-5696106-A | Steroids useful as anti-cancer and anti-obesity agents | RESEARCH CORPORATION TECHNOLOGIES, INC. (US) | 1997-12-09 | — | — | US | disclosed |
| US-5656621-A | ADMINISTERING ANTIDIABETIC, ANTIAGING, ANTIHYPERCHOLESTROLEMIC, ANTIHYPERGLYCEMIC AGENT | RESEARCH CORPORATION TECH., INC. (US) | 1997-08-12 | — | — | US | disclosed |
| US-5157031-A | Androsterone derivatives | RESEARCH CORPORATION TECHNOLOGIES, INC. (US) | 1992-10-20 | — | — | US | disclosed |
| EP-0246650-B1 | STEROIDS USEFUL AS ANTI-CANCER AND ANTI-OBESITY AGENTS, A THERAPEUTIC COMPOSITION CONTAINING THEM AND USE THEREOF FOR THE PREPARATION OF A THERAPEUTIC COMPOSITION | RESEARCH CORPORATION TECHNOLOGIES, INC. (US) | 1992-01-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120030779-A1 | COMPOSITIONS AND METHODS FOR DETECTING, TREATING, OR PREVENTING REDUCTIVE STRESS | TNNC1, TNNI3, HSPA5 | CYP19A1 4684/4885G6PD 1672/4885HSD17B3 2476/4885 |
| US-20140220152-A1 | Compositions and Methods for Detecting, Treating, or Preventing Reductive Stress | TNNC1, TNNI3, TXN2 | CYP19A1 4514/4885G6PD 504/4885HSD17B3 2296/4885 |
| US-20150071904-A1 | COMPOSITIONS AND METHODS TO BOOST ENDOGENOUS ROS PRODUCTION FROM BACTERIA | ROS1, NOX4, CYBB | CYP19A1 2089/4885G6PD 255/4885HSD17B3 1502/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.